十一月 2025
- Home
- Monte Rosa Therapeutics, Inc.
十一月 2025的Monte Rosa Therapeutics,...市场份额分析
Pioneering Therapies for Cancer and Beyond – Our drug discovery platform is tailored to promote specific protein ubiquitination and subsequent proteasomal degradation of disease-causing, undruggable proteins, in essence leading to pharmacological protein knockout with high efficiency and accuracy.
Monte Rosa Therapeutics, Inc.(包含公司地区分支机构)
查看更多网站流量和参与度信息- monterosatx.com
Monte Rosa Therapeutics, Inc.收入截至 十一月 2025为 75M - 100M
Monte Rosa Therapeutics, Inc.主要域名产生的收入
3 年中Monte Rosa Therapeutics, Inc.主要域名的收入
Monte Rosa Therapeutics, Inc.主要域名的收入
Monte Rosa Therapeutics, Inc.热门域名的总访问量
了解Monte Rosa Therapeutics, Inc.市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Monte Rosa Therapeutics, Inc.热门域名的平均访问时长
分析Monte Rosa Therapeutics, Inc.参与度指标。
过去 3 个月的平均访问时长
子公司明细
Monte Rosa Therapeutics, Inc.热门域名的平均页面浏览量
了解Monte Rosa Therapeutics, Inc.如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Monte Rosa Therapeutics, Inc. 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Monte Rosa Therapeutics Inc. launches preclinical data on MRT-6160.Biotechnology company Monte Rosa Therapeutics has released preclinical data on MRT-6160, a molecular glue degrader (MGD) to treat autoimmune and inflammatory diseases.
十月 30, 2025阅读更多
新闻Monte Rosa Therapeutics Inc. attends event ACR Convergence 2025.Monte Rosa Therapeutics presents preclinical data at ACR Convergence 2025 on the potential of MRT-6160, a VAV1-directed molecular glue degrader, to treat immune-mediated diseases.
十月 24, 2025阅读更多
新闻Monte Rosa Therapeutics Inc. is developing protein degraders.Monte Rosa Therapeutics Inc, founded in Basel in 2018, can look forward to an upfront payment of US$120m for its second collaboration and licensing deal with Novartis AG to develop protein degraders.
九月 16, 2025阅读更多
查看 Monte Rosa Therapeutics, Inc. 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。